Skip to main content
Premium Trial:

Request an Annual Quote

Vizgen Raises $85.2M in Series C Financing

NEW YORK – Spatial genomics firm Vizgen said on Friday that it has raised $85.2 million in a Series C financing round.

Blue Water Life Science Advisors and Arch Venture Partners led the round, joined by Sofina, Northpond Ventures, Tao Capital Partners, Novalis LifeSciences, David Walt, and others.

Vizgen said it plans to use the proceeds to increase adoption of its Merscope single-cell spatial transcriptomics platform, which the company showcased a year ago and started making broadly commercially available in the US earlier this year. Merscope is based on multiplex error-robust fluorescence in situ hybridization (MERFISH) technology developed by researchers at Harvard.

"We are still only at the cusp of what we can provide our customers in our quest to improve human health," CEO Terry Lo said in a statement.

The Cambridge, Massachusetts-based firm closed a $37 million Series B financing round in April 2021 and a $14 million Series A round in January 2020.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.